organization of resources, maintains liaison and coordination of programs within the Federal, voluntary, and private sectors involved in the provision of services to people with diabetes.

Matters to be Discussed: Agenda items include a discussion of public health issues pertinent to the role of economic analysis in the Division of Diabetes Translation (DDT) priorities, as well as, the challenges of diabetes in Latino/Hispanic communities. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Margaret Hurd, Committee Management Specialist, DDT, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE, M/S K–10, Atlanta, Georgia 30341–3724, telephone 770/488–5505.

Dated: August 25, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–23189 Filed 8–28–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Proposed Information Collection Activity; Comment Request

Proposed Projects: *Title:* Request for State Data to Determine the Tribal Family Assistance Grant Amount.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
Request	18	1	42	756.

Estimated Total Annual Burden Hours: 756

In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, Division of Information Resource Management Services, 370 L'Enfant Promenade, S.W., Washington, D.C. 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: August 25, 1997.

Bob Sargis,

Acting Reports Clearance Officer.

[FR Doc. 97–23088 Filed 8–28–97; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Immunology Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 19, 1997, 9:30 a.m. to 5 p.m.

Location: Parklawn Bldg., conference rooms D and E, 5600 Fishers Lane, Rockville, MD.

Contact Person: Peter E. Maxim, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–1293, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12516. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will hear presentations from FDA staff regarding new review initiatives pertinent to types of submissions generally reviewed by the committee. FDA will also present a first year summary of activities associated with the down classification of tumor markers used for monitoring cancer patients. FDA seeks to obtain committee input on the data requirements for class II submissions of tumor markers with the intent of modifying the guidance document that serves as a special control for these class II products. Single copies of the guidance document entitled ''Guidance For Submission Of Tumor Marker Premarket Notifications'' can be obtained by contacting the Division of Small Manufacturers Assistance, 1350 Piccard Dr., Rockville, MD 20851, 1–800–638–2041 or 301–443–6597, or on the Internet using the World Wide Web (WWW) (http://www.fda.gov/cdrh/draftgui.html).

Procedure: On September 19, 1997, from 10 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending